Samsung Biologics to spin off CDMO business from biosimilars
Samsung Biologics, the biopharmaceutical arm of Samsung Group, will completely separate its contract development and manufacturing organization (CDMO) business from its biosimilar operations after shareholders approved a spin-off plan Friday.
